Biomarkers: Technological and Commercial Outlook 2012-2022

• Publication date: July 2012
• Report size: 162 pages

Report Details Biomarkers - discover market outlooks and industry trends What are the prospects for biomarker research, products and services? Visiongain's report shows you potential revenues and other trends to 2022, discussing data, outlooks and opportunities. Our new study analyses the commercial potential for biomarker products and services. You find projected revenues to 2022 at world market, submarket, leading scient...

Report Details
Biomarkers - discover market outlooks and industry trends

What are the prospects for biomarker research, products and services? Visiongain's report shows you potential revenues and other trends to 2022, discussing data, outlooks and opportunities.

Our new study analyses the commercial potential for biomarker products and services. You find projected revenues to 2022 at world market, submarket, leading scientific discipline, leading indication and national market level. 

Analysis of submarkets and scientific areas

You see world-level forecasting for the following submarkets:
• Biomarker development and technologies
• Biomarker diagnostics
• Biomarker services.

Also, you receive revenue forecasts to 2022 by scientific discipline:
• Genomics
• Proteomics
• Bioinformatics.

How will leading countries perform?

Our study gives revenue forecasts to 2022 for nine prominent national markets:
• US
• Japan
• France, Germany, UK, Spain and Italy (EU5 countries)
• China
• India.

Technological research in leading markets will drive worldwide growth in revenues for biomarker products and services from 2012 to 2022, our investigation shows.

You discover prospects for leading therapeutic sectors for biomarker diagnostics and research

Our report also analyses leading therapeutic market areas for biomarker applications. You receive revenue forecasts for three therapeutic submarkets to 2022:
• Cancer
• Cardiovascular disease
• CNS diseases.

What issues decide the future of the industry and market?

Our study helps you assess industry trends and market outlooks. You find discussions of many issues and developments:
• Intellectual property for biomarkers
• Regulatory guidance for biomarker validation and qualification
• Improvements to discovery instruments and tools
• Outsourcing biomarker discovery and development
• Collaboration between public institutions and the pharmaceutical industry
• Challenges in co-developing drugs and diagnostics.

Our work gives you multi-level business research and analysis with sales predictions. You see how that industry and market can perform to 2022.

Biomarker products and technologies: market growth and commercial prospects from 2012
Where is the biomarkers market heading? Overall revenues for biomarker products and services will rise from 2012-2022, our report forecasts. 

There is great demand for accurate, non-invasive diagnostics. Development of tests for disease diagnosis, prognosis and treatment responses gives opportunities for companies seeking to enter the biomarkers market. Our report shows you and explains.

What about developments in new areas of research? Epigenomics, metabolomics and microRNA hold promise as new sources of disease biomarkers, our analyses show.

How can companies harness the potential that biomarkers offer in drug discovery and development?

Discover profiles for prominent companies

Our report profiles leading companies operating in each market sector, assessing the technologies, products and services of twelve CROs, seven technology providers and seven diagnostics manufacturers, including these:
• Covance
• Charles River Laboratories
• Caprion Proteomics
• Affymetrix
• AB SCIEX
• Life Technologies
• Quest Diagnostics
• Myriad Genetics
• Genomic Health.

Our study also covers the role of pharmaceutical companies in the biomarkers market. You see recent developments for eight leading pharma companies.

Market forecasts, R&D trends, company and segment analyses and discussions of industry prospects

In visiongain's study you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and commercial developments. You receive 56 tables, 53 charts and two research interviews.

Nine ways Biomarkers: Technological and Commercial Outlook 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the overall world market and submarkets
• Discover forecasted revenue trends by therapeutic sector to 2022
• Find projected biomarker revenues for 3 leading scientific disciplines to 2022
• Assess 26 prominent companies, discovering activities and outlooks
• Analyse market prospects for 8 leading pharma companies adopting biomarkers in drug discovery and development
• See market forecasting to 2022 for the US, Japan, 5 leading EU countries, Chinaand India
• Review technological, regulatory and commercial developments, assessing trends and prospects
• Find out what will stimulate and restrain the industry and market from 2012
• View opinions from our survey, seeing interviews with market participants.

There you find quantitative and qualitative analyses with independent predictions. You receive information unique to our report, helping you stay informed on business intelligence.

Gain research and analysis on the biomarkers market now

Our study is for everybody needing biomarker industry and market analyses. You find data, predictions and answers there. Please order that report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6 

Global Genomics Industry

Table of Contents

1. Executive Summary
1.1 Biomarkers: World Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Market Definition 2012

2. An Introduction to the Concept and Use of Biomarkers
2.1 Definition of a Biomarker
2.1.1 A Brief History of Biomarkers
2.1.2 The Importance of Biomarkers
2.2 Biomarker Discovery and Validation
2.3 Uses of Biomarkers
2.3.1 Assessing Drug Efficacy
2.3.2 Assessing Drug Safety
2.3.3 Companion Diagnostics
2.3.3.1 CLIA vs. FDA Approval
2.3.4 Therapeutic Importance of Biomarkers
2.3.5 Imaging Biomarkers
2.3.5.1 Imaging Biomarkers in Clinical Trials
2.4 Biomarkers and Personalised Medicine
2.5 Biomarker Discovery
2.5.1 Genomics
2.5.1.1 Pharmacogenomics
2.5.2 Proteomics
2.5.3 Metabolomics

3. The World Biomarkers Market 2012-2022
3.1 The World Biomarkers Market 2011
3.1.1 The Biomarkers Market by Sector 2011
3.1.2 The Biomarkers Market by Discipline 2011
3.2 The Biomarkers Market: Overall Revenue Forecast 2012-2022
3.3 The Biomarker Development and Technologies Submarket 2011
3.3.1 The Biomarker Development and Technologies Submarket: Revenue Forecast 2012-2022
3.4 The Biomarker Diagnostics Submarket 2011
3.4.1 The Biomarker Diagnostics Submarket: Revenue Forecast 2012-2022
3.5 The Biomarker Services Submarket 2011
3.5.1 The Biomarker Services Submarket: Revenue Forecast 2012-2022
3.6 Growth in Key Biomarker Disciplines 2012-2022
3.6.1 The Genomics Submarket: Revenue Forecast 2012-2022
3.6.1.1 Next Generation Sequencing to Drive Growth
3.6.2 The Proteomics Submarket: Revenue Forecast 2012-2022
3.6.3 The Bioinformatics Submarket: Revenue Forecast 2012-2022

4. Leading Indications for Biomarker Discovery and Development 2012-2022
4.1 The World Biomarkers Market by Indication 2011
4.2 The World Biomarkers Market by Indication 2012-2022
4.3 Cancer Biomarker Submarket 2012-2022
4.3.1 A Brief History of Cancer Biomarker Research
4.3.2 The State of Cancer Biomarker Research 2011
4.3.2.1 Cancer Genome Atlas
4.3.3 Many Cancer Diagnostics Are Reaching the Market
4.3.4 Opportunities and Challenges for Cancer Biomarkers
4.3.4.1 Prostate Cancer
4.3.4.2 Lung Cancer
4.3.5 Cancer Biomarker Submarket: Revenue Forecast 2012-2022
4.4 Cardiovascular Disease Biomarker Submarket 2012-2022
4.4.1 A Brief History of Cardiovascular Biomarker Research
4.4.2 The State of Cardiovascular Biomarker Research 2011
4.4.3 Cardiovascular Disease Diagnostics
4.4.4 The Future of Cardiovascular Biomarker Research
4.4.5 Cardiovascular Disease Biomarker Submarket: Revenue Forecast 2012-2022
4.5 CNS Diseases Biomarker Submarket 2012-2022
4.5.1 The State of CNS Disease Biomarker Research 2011
4.5.2 Biomarker-Based Diagnostics for CNS Diseases
4.5.2.1 DiaGenic
4.5.3 Neuroimaging Biomarkers
4.5.4 CSF Biomarkers
4.5.5 Alzheimer's Disease
4.5.6 Multiple Sclerosis
4.5.7 Parkinson's Disease
4.5.8 CNS Diseases Biomarker Submarket: Revenue Forecast 2012-2022

5. Leading National Biomarker Markets 2012-2022
5.1 The Biomarkers Market: Regional Breakdown 2011
5.2 The Biomarkers Market: Regional Forecast 2012-2022
5.3 The US
5.3.1 The US: Biomarker Revenues 2012-2022
5.4 Leading EU Markets
5.4.1 Increased Funding for Biomarker Research in the UK
5.4.2 Leading EU Markets: Biomarker Revenues 2012-2022
5.5 Japan
5.5.1 Japan: Biomarker Revenues 2012-2022
5.6 China
5.6.1 Companies Entering the Chinese Market
5.6.2 LightArray Biotech
5.6.3 China: Biomarker Revenues 2012-2022
5.7 India
5.7.1 India: Biomarker Revenues 2012-2022

6. Biomarker Industry Trends 2012-2022
6.1 Strengths and Weaknesses in the Biomarkers Market 2011
6.2 Opportunities and Threats in the Biomarkers Market 2012-2022
6.3 Biomarkers Market: STEP Analysis
6.4 Social Factors
6.4.1 Patient Stratification
6.4.2 Biomarker Hype
6.4.3 Emphasis on Oncology
6.5 Technological Factors
6.5.1 Decreasing Size, Increasing Sensitivity
6.5.1.1 ABT Molecular Imaging
6.5.2 Data Storage
6.6 Economic Factors
6.6.1 Biomarkers: Cutting the Cost of Drug Development
6.6.1.1 Toxicity Biomarkers
6.6.2 The Cost of Technology
6.6.3 Outsourcing Biomarker Discovery and Development
6.7 Political Factors
6.7.1 Public-Private Partnerships
6.7.2 Improving Regulatory Guidelines
6.7.3 Biomarker Intellectual Property
6.8 Challenges in Developing Biomarkers
6.9 Combining Drug and Diagnostic Development
6.10 MicroRNA Biomarkers
6.11 Big Pharma and Biomarkers
6.11.1 Pfizer
6.11.2 Novartis
6.11.3 Merck & Co.
6.11.4 Sanofi
6.11.5 Roche
6.11.5.1 Roche Diagnostics
6.11.5.2 Ventana Medical Systems
6.11.5.3 Roche 454 Life Sciences
6.11.6 GSK
6.11.7 AstraZeneca
6.11.8 Abbott Laboratories/Abbott Molecular

7. Companies Participating in the Biomarkers Market 2012
7.1 Biomarker Service Providers
7.1.1 Global CROs and Biomarkers
7.1.1.1 Not All Global CROs Are Investing in Biomarkers
7.1.2 Quintiles
7.1.3 Covance
7.1.4 Parexel
7.1.5 Charles River Laboratories
7.1.6 ICON
7.1.7 WuXi AppTec
7.1.8 Caprion Proteomics
7.1.9 Proteome Sciences
7.1.10 Pacific Biomarkers
7.1.11 Oxford Gene Technology
7.1.12 NextGen Sciences
7.2 Biomarker Technology Providers
7.2.1 Affymetrix
7.2.1.1 QuantiGene
7.2.2 Agilent
7.2.2.1 Agilent and Diagnostics
7.2.3 AB SCIEX
7.2.4 QIAGEN
7.2.5 Life Technologies
7.2.6 Axela
7.2.7 Thermo Fisher Scientific
7.2.7.1 Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center
7.3 Biomarker Diagnostic Developers
7.3.1 Quest Diagnostics
7.3.2 Myriad Genetics
7.3.2.1 Pipeline
7.3.2.2 Myriad RBM
7.3.3 Genomic Health
7.3.4 Critical Diagnostics
7.3.5 BG Medicine
7.3.6 Epigenomics
7.3.6.1 Diagnostic Product Portfolio
7.3.7 MDxHealth

8. Opinions from Our Survey: Research Interviews
8.1 Dr Dan Chelsky, CSO, Caprion Proteomics
8.1.1 The Advantages to Outsourcing in the Biomarker Industry
8.1.2 Biomarkers and Bioinformatics
8.1.3 Caprion's Proteomics Services
8.1.4 Future Opportunities in Proteomics
8.1.5 Therapeutic Focus of Biomarker Research
8.1.6 Alliances in Biomarker Services
8.1.7 Increasing Interest from the Pharmaceutical Industry
8.1.8 Proteomics and Diagnostics
8.2 Dr James Snider, President, Critical Diagnostics
8.2.1 Development of Biomarkers and Diagnostics
8.2.1.1 The Cost of Development
8.2.2 Growth in Cardiology Biomarkers and Diagnostics
8.2.3 Critical Diagnostics' Presage ST2 Assay
8.2.4 The Importance of the US Market
8.2.5 Companies Competing in the Market
8.2.6 Opportunities in Cardiac Biomarkers

9. Conclusions
9.1 State of the World Biomarkers Market in 2011
9.2 Growth in the World Biomarkers Market 2012-2022
9.2.1 Dominance of Leading Western Markets
9.3 The Use of Biomarkers in Drug Discovery and Development
9.4 Demand for New Diagnostics

List of Tables

Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Selected Drugs with Pharmacogenomic Biomarkers Listed on their Labels, 2012
Table 2.2 Selected Clinically-Relevant Cancer Biomarkers, 2012
Table 2.3 Technologies and Platforms for Biomarker Research, 2012
Table 3.1 World Biomarkers Market by Sector, 2011
Table 3.2 World Biomarkers Market by Discipline, 2011
Table 3.3 World Biomarkers Market: Overall Market and Revenue Forecasts by Sector, 2011-2022
Table 3.4 Biomarker Sector Submarket Shares, 2011-2022
Table 3.5 Biomarker Development and Technologies Submarket: Revenue Forecast, 2011-2022
Table 3.6 Biomarker Diagnostics Submarket: Revenue Forecast, 2011-2022
Table 3.7 Biomarker Services Submarket: Revenue Forecast, 2011-2022
Table 3.8 Biomarker Discipline Submarket Shares, 2011-2022
Table 3.9 Genomics Submarket: Revenue Forecast, 2011-2022
Table 3.10 Selected Producers of Single-Molecule Sequencing Technologies, 2012
Table 3.11 Proteomics Submarket: Revenue Forecast, 2011-2022
Table 3.12 Bioinformatics Submarket: Revenue Forecast, 2011-2022
Table 4.1 World Biomarkers Market by Indication, 2011
Table 4.2 Biomarker Indication Submarket Shares, 2011-2022
Table 4.3 Selected Marketed Biomarker-Based Cancer Diagnostics, 2012
Table 4.4 Selected ALK Inhibitors in Development for Lung Cancer, 2012
Table 4.5 Cancer Submarket: Revenue Forecast, 2011-2022
Table 4.6 Cardiovascular Disease Submarket: Revenue Forecast, 2011-2022
Table 4.7 CNS Diseases Submarket: Revenue Forecast, 2011-2022
Table 5.1 Biomarkers: Market Shares by Country, 2011
Table 5.2 World Biomarkers Market: Revenue Forecasts by Country, 2011-2022
Table 5.3 National Biomarker Submarket Shares, 2011-2022
Table 5.4 US Submarket: Revenue Forecast, 2011-2022
Table 5.5 Top Five EU Submarkets: Revenue Forecasts, 2011-2022
Table 5.6 Japanese Submarket: Revenue Forecast, 2011-2022
Table 5.7 Chinese Submarket: Revenue Forecast, 2011-2022
Table 5.8 Indian Submarket: Revenue Forecast, 2011-2022
Table 6.1 World Biomarkers Market: Strengths and Weaknesses, 2011-2012
Table 6.2 World Biomarkers Market: Opportunities and Threats, 2012-2022
Table 6.3 World Biomarkers Market: STEP Analysis, 2012-2022
Table 6.4 Cancer Deaths by Tumour Type, 2008
Table 6.5 Selected Cancer Therapies Approved With a Biomarker, 2011
Table 6.6 PSTC Biomarkers in Development, 2012
Table 6.7 Average Cost of Sequencing the Human Genome 2000-2011
Table 6.8 IMI-Funded Biomarker Projects, 2009-2012
Table 6.9 Drug Discovery Outsourcing: Overall Market and Subsector Forecast, 2011, 2016 & 2022
Table 7.1 ICON: Frequently Requested Laboratory Biomarkers, 2012
Table 7.2 Proteome Sciences: Revenue, 2010-2011
Table 7.3 NextGen Group: Revenue by Region, 2011
Table 7.4 Affymetrix: Revenue by Division, 2009-2011
Table 7.5 Myriad Genetics: Biomarker Product Portfolio, 2012
Table 7.6 Myriad Genetics: Revenue by Product, 2010-2011
Table 7.7 Myriad Genetics: Diagnostic Pipeline, 2012
Table 7.8 Genomic Health: Revenue by Division, 2009-2011
Table 7.9 BG Medicine: Revenue by Division, 2009-2011
Table 7.10 Epigenomics: Revenue by Half-Year, 2010-2011
Table 7.11 MDxHealth: Pipeline, 2012
Table 7.12 MDxHealth: Revenue by Source, 2009-2011
Table 9.1 World Biomarkers Market: Revenues by Sector, 2011, 2016 and 2022
Table 9.2 World Biomarkers Market: Revenues by Discipline, 2011, 2016 and 2022
Table 9.3 World Biomarkers Market: Revenues by Disease, 2011, 2016 and 2022
Table 9.4 World Biomarkers Market: Revenues by Country, 2011, 2016 and 2022

List of Figures

Figure 2.1 Definitions of a Biomarker, 2012
Figure 2.2 The Biomarker Discovery and Validation Process, 2012
Figure 3.1 World Biomarkers Market by Sector, 2011
Figure 3.2 World Biomarkers Market by Discipline, 2011
Figure 3.3 World Biomarkers Market: Drivers and Restraints, 2012-2022
Figure 3.4 World Biomarkers Market: Overall Market Forecast, 2011-2022
Figure 3.5 Biomarkers: Market Shares by Sector, 2016
Figure 3.6 Biomarkers: Market Shares by Sector, 2022
Figure 3.7 Biomarker Development and Technologies Submarket: Drivers and Restraints, 2012-2022
Figure 3.8 Biomarker Development and Technologies Submarket: Revenue Forecast, 2011-2022
Figure 3.9 Biomarker Diagnostics Submarket: Revenue Forecast, 2011-2022
Figure 3.10 Biomarker Diagnostics Submarket: Drivers and Restraints, 2012-2022
Figure 3.11 Biomarker Services Submarket: Drivers and Restraints, 2012-2022
Figure 3.12 Biomarker Services Submarket: Revenue Forecast, 2011-2022
Figure 3.13 Biomarkers: Market Shares by Discipline, 2016
Figure 3.14 Biomarkers: Market Shares by Discipline, 2022
Figure 3.15 Genomics Submarket: Revenue Forecast, 2011-2022
Figure 3.16 Genomics Submarket: Drivers and Restraints. 2012-2022
Figure 3.17 Proteomics Submarket: Drivers and Restraints, 2012-2022
Figure 3.18 Proteomics Submarket: Revenue Forecast, 2011-2022
Figure 3.19 Bioinformatics Submarket: Revenue Forecast, 2011-2022
Figure 3.20 Bioinformatics Submarket: Drivers and Restraints, 2012-2022
Figure 4.1 World Biomarkers Market by Indication, 2011
Figure 4.2 Biomarkers: Market Shares by Indication, 2016
Figure 4.3 Biomarkers: Market Shares by Indication, 2022
Figure 4.4 Cancer Submarket: Revenue Forecast, 2011-2022
Figure 4.5 Cardiovascular Disease Submarket: Revenue Forecast, 2011-2022
Figure 4.6 CNS Diseases Submarket: Revenue Forecast, 2011-2022
Figure 5.1 Biomarkers: Market Shares by Country, 2011
Figure 5.2 Biomarkers: Market Shares by Country, 2016
Figure 5.3 Biomarkers: Market Shares by Country, 2022
Figure 5.4 US Submarket: Revenue Forecast, 2011-2022
Figure 5.5 Top Five EU Submarkets: Revenue Forecasts, 2011-2022
Figure 5.6 Japanese Submarket: Revenue Forecast, 2011-2022
Figure 5.7 Chinese Submarket: Revenue Forecast, 2011-2022
Figure 5.8 Indian Submarket: Revenue Forecast, 2011-2022
Figure 6.1 Cancer Deaths by Tumour Type, 2008
Figure 6.2 Average Cost of Sequencing the Human Genome 2000-2005
Figure 6.3 Average Cost of Sequencing the Human Genome 2006-2011
Figure 6.4 Drug Discovery Outsourcing: Overall Market and Subsector Forecasts, 2011, 2016 & 2022
Figure 7.1 ICON: Frequently Requested Laboratory Biomarkers, 2012
Figure 7.2 Proteome Sciences: Revenue, 2010-2011
Figure 7.3 NextGen Group: Revenue by Region, 2011
Figure 7.4 Affymetrix: Revenue by Division, 2009-2011
Figure 7.5 Myriad Genetics: Revenue by Product, 2010-2011
Figure 7.6 Genomic Health: Product Revenue, 2009-2011
Figure 7.7 BG Medicine: Product Revenue, 2009-2011
Figure 7.8 Epigenomics: Revenue by Half-Year, 2010-2011
Figure 7.9 MDxHealth: Revenue by Source, 2009-2011
Figure 9.1 World Biomarkers: Revenues Market by Sector, 2011, 2016 and 2022
Figure 9.2 World Biomarkers Market: Revenues by Discipline, 2011, 2016 and 2022
Figure 9.3 World Biomarkers Market: Revenues by Disease, 2011, 2016 and 2022
Figure 9.4 World Biomarkers Market: Revenues by Country, 2011, 2016 and 2022 

Companies Listed

454 Life Sciences (a subsidiary of Roche)
AB SCIEX (a subsidiary of Danaher)
Abbott Laboratories
Abbott Molecular
Abcodia
ABT Molecular Imaging
ACS Biomarker
Advanced Cell Diagnostics (ACD)
Advion Bioanalytical Labs (part of Quintiles)
Affymetrix
Agendia
Agilent
Alacris Theranostics
Alere
Amarantus BioSciences
Amgen
Applied Biosystems (part of Life Technologies)
Arctic Partners
ARIAD Pharmaceuticals
Arizona State University
Arrayit Diagnostics
ARUP Laboratories
Association for Molecular Pathology (AMP) [US]
Athena Diagnostics (a subsidiary of Quest Diagnostics)
Atherotech Diagnostics Lab
Aushon Biosystems
Axela
Bayer
Belfer Institute for Applied Cancer Science [US]
Berkeley HeartLab (a subsidiary of Quest Diagnostics)
BG Medicine
BGI (formerly Beijing Genomics Institute)
Biosoft
BRAHMS (part of Thermo Fisher Scientific)
Brigham and Women's Hospital
Bristol-Myers Squibb
British Heart Foundation [UK]
Broad Institute [US]
Cancer Research Technology
Cancer Research UK
Caprion Proteomics
Celera (part of Quest Diagnostics)
Celgene
Cell Signaling Technology
Celldex Therapeutics
Centers for Medicare and Medicaid Services (CMS) [US]
Cephalon (part of Teva)
Charles River Laboratories
Chronix Biomedical
Ciphergen Biosystems
Clarient
Cleveland HeartLab
Clinigene International
Commonwealth Scientific and Industrial Research Organisation (CSIRO) [Australia]
Comprehensive Biomarker Center (formerly febit)
Covance
Critical Diagnostics
Critical Path Institute (C-Path) [US]
Daiichi Sankyo
Dako (now part of Agilent)
Dana-Farber Cancer Institute [US]
Danaher
DiaGenic
Durin Technologies
DxS (now part of QIAGEN)
Eisai
EKO Diagnostic
Eli Lilly
Epigenomics
Epistem
EQT
ETH Zurich
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Stroke Research Network for Hypothermia (Euro-HYP)
Evotec
Exact Sciences
Exiqon
Exonhit
Ezose Sciences (part of Shionogi)
Food and Drug Administration (FDA) [US]
Foundation Medicine
Fujirebio Diagnostics
GE Healthcare
Genetic Technologies
Geneva Bioinformatics (GeneBio)
Genomic Health
GenWay Biotech
Great Point Partners
GSK
Health Diagnostic Laboratory 
HealthLinx
Helicos BioSciences
Hewlett-Packard
Hirosaki University
HTG Molecular Diagnostics
Human Proteome Organisation (HUPO)
ICON
Insight Genetics
Integrated Diagnostics
International Cancer Genome Consortium (ICGC)
Ipsogen (a subsidiary of QIAGEN)
Isogen Life Science
Johnson & Johnson (J&J)
KU Leuven (University of Leuven)
LabCorp
Les entreprises du médicament (LEEM) [France]
Life Technologies
LightArray Biotech
Malmö University
Massachusetts General Hospital
Max Planck Institute for Molecular Genetics [Germany]
Mayo Clinic [US]
Mayo Collaborative Services 
MDxHealth
Medical Research Council [UK]
Memorial Sloan-Kettering Cancer Center [US]
Merck & Co.
Merck KGaA
Metabolon
Michael J Fox Foundation
Myriad Genetics
Myriad RBM (formerly Rules-Based Medicine, part of Myriad Genetics)
National Academy of Sciences (NAS) [US]
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Human Genome Research Institute (NHGRI) [US]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute of Allergy and Infectious Diseases (NIAID) [US]
National Institute on Aging (NIA) [US]
National Jewish Health [US]
Nephromics
Newcastle University [UK]
NextGen Group
NextGen Sciences
NextGen Sciences Dx
Novartis
Novartis Molecular Diagnostics (part of Novartis)
NovioGendix
Oncoimmune
OpGen
OPKO Health
Orion Genomics
Oslo University Hospital
Oxford Cancer Biomarkers
Oxford Gene Technology (OGT)
Pacific Biomarkers
Pacific Biosciences
Panomics (now part of Affymetrix)
Parexel
Pathwork Diagnostics
Personal Genome Diagnostics
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
PLUS Diagnostics
Power3 Medical Products
PPD
PPD Biomarker Discovery Services (now part of Caprion Proteomics)
Predictive Biosciences
Predictive Safety Testing Consortium (PSTC) [US]
Prometheus Laboratories
Proteome Sciences
QIAGEN
QLIDA Diagnostics
Quanterix
Quanticel Pharmaceuticals
Quest Diagnostics
Quintiles
Randox Laboratories
Roche
Roche Diagnostics (part of Roche)
SABiosciences (now part of QIAGEN)
Sandor Proteomics
Santaris Pharma
Seattle Genetics
Shanghai Jiao Tong University
Shionogi
Siemens
Siena Biotech
SMA Foundation [US]
Stanford University
State Food and Drug Administration (SFDA) [China]
Stemina Biomarker Discovery 
Sysmex
Takeda Pharmaceutical
Targeted Molecular Diagnostics (now part of Quintiles)
Technion-Israel Institute of Technology 
Technology Strategy Board (TSB) [UK]
Teva Pharmaceutical Industries
Thallion Pharmaceuticals
The Biomarkers Consortium
Thermo Fisher Scientific
Trans-Hit Biomarkers
Tufts Center for the Study of Drug Development
University of Alabama
University of Medicine and Dentistry of New Jersey (UMDNJ)
University of Oklahoma College of Pharmacy
University of Oslo
University of Turku
University of Washington
Ventana Medical Systems
Vertex Pharmaceuticals
Warnex
Wellcome Trust Sanger Institute [UK]
World Health Organization (WHO)
WuXi AppTec
Xcovery